ReiThera Srl is a clinical-stage biopharmaceutical company that aims to unlock the potential of an adenovirus vector gene-delivery platform, previously developed by Okairos and now owned by GlaxoSmithKline (GSK). ReiThera Srl is developing vaccines exclusively for GSK and actively explores applications of adeno-vectored vaccines technology in other fields.
Okairos was acquired by GSK in May 2013. After the divestment of Okairos Srl to Keires AG, Okairos Srl changed its name to ReiThera Srl.
Our team pioneered the development, manufacture and early clinical testing of non-human origin adeno-vectored vaccines for major infectious diseases, including hepatitis C, malaria, HIV, respiratory syncytial virus and Ebola. These assets are now owned by GSK.
Our expertise in designing, constructing and manufacturing adenovirus vector-based vaccines is focused on the next generation of prophylactic and therapeutic GSK vaccine programs, some of which are being developed through partnerships.